CareLit Fachartikel

FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)

Christoph-Ferdinand Wielenberg, Johannes Christian Fostitsch, Christian Volz, Reinhard Marks, Kerstin Michalski, Ralph Wäsch, Robert Zeiser, Juri Ruf, Philipp T Meyer, Claudius Klein · Nuklearmedizin - NuclearMedicine · 2024 · Heft 04 · S. 252-258

Dokument
912722
CareLit-ID
Jahr
2024
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Nuklearmedizin - NuclearMedicine
Autor:innen
Christoph-Ferdinand Wielenberg, Johannes Christian Fostitsch, Christian Volz, Reinhard Marks, Kerstin Michalski, Ralph Wäsch, Robert Zeiser, Juri Ruf, Philipp T Meyer, Claudius Klein
Ausgabe
Heft 04 / 2024
Jahrgang 63
Seiten
252-258
Erschienen: 2024-08-01 00:00:00
ISSN
0029-5566
DOI
10.1055/a-2283-8417

Zusammenfassung

Abstract Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment especially for Non-Hodgkin-Lymphoma (NHL). This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis. We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score…

Schlagworte

DLBCL MCL CAR T-cell FDG-PET/CT Nuklearmedizin - NuclearMedicine